Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al

Zinal S Chheda,1 Sabine Mueller,2,3,4,5 Bindu Hegde,6 Akane Yamamichi,2 Lisa H Butterfield,7,8 Hideho Okada1,5,7,9

We read with interest the article entitled, ‘H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma’ (DMG).1 In this report, the investigators isolated an H3.3K27M-specific T cell receptor (TCR) from transgenic mice expressing a diverse human TCR repertoire and human HLA-A*02:01. They observed a high functional avidity of human T cells transduced with the TCR. They also tested another TCR (1H5) we reported.2 However, unlike our published study,2 the T cells transduced with either H3.3K27M-reactive TCR failed to recognize HLA-A*02:01+tumor cells that endogenously express H3.3K27M. The investigators used CRISPR/Cas9 editing to mitigate the mispairing of endogenous versus transgene TCR α- and β-chains. The investigators conclude that the H3.3K27M mutation is not a suitable target for H3.3K27M+ DMG, most likely due to insufficient epitope processing and presentation in HLA-A*02:01.

The investigators had different observations than those in our publication.2 They included HLA-A*02:01+U87 glioma cells transduced with full-length H3.3K27M cDNA. Although a different vector and transduction method may have been used, our study also used U87 cells expressing transgene-derived full-length H3.3K27M cDNA. While their liquid chromatography-tandem mass spectrometry (LC-MS/MS) failed to detect endogenously processed mutant H3.3-derived peptides in U87MG cells overexpressing full-length H3.3K27M cDNA, we reported the detection of such by LC-MS/MS in the HLA-A2+ derived HLA-A2+ U87 cells expressing the mutant cDNA.2 Accordingly, we demonstrated that human T cells transduced with a retroviral vector, which incorporates the TCR (clone 1H5) α-chains and β-chains as well as siRNA targeting constant regions of the endogenous TCR α- and β-chains, mediated an antigen-specific cytotoxic activity against the U87 cells expressing the full-length H3.3K27M cDNA.2 In addition to the lactate dehydrogenase assay data that we reported,2 we recently implemented a live cell imaging system (the xCEL-Ligence system) and reproduced the same data (figure 1). The different observations with the U87 cell line may have been due to the different levels of the mutant H3.3 expression and the use of the retroviral TCR vector that also encoded the siRNA against endogenous TCR. In our hands, the siRNA-based disruption of endogenous TCR has been more effective than the CRISPR/Cas9-based system. Furthermore, these T cells could mediate antigen-specific killing of patient-derived HLA-A*02:01+H3.3K27M+DMG cells (figure 1). Nevertheless, we agree with the investigators that the endogenous presentation of the H3.3K27M epitope in HLA-A*02:01 may not be robust. We are currently evaluating whether standard-of-care treatment and resulting stress on histone and DNA (eg, ionizing radiation and chemotherapy) can enhance the presentation of the epitope.

There are additional indirect but supporting observations regarding the clinical relevance of the H3.3K27M (26-35) epitope. Around the same time as our report,2 Dr Michael Platten’s group at University of Heidelberg also described H3.3K27M (26-35) as a cytotoxic T lymphocyte (CTL) epitope.3 Importantly, in their studies, H3.3K27M-specific CTLs...
were exclusively detected in peripheral blood mononuclear cell samples derived from three of three patients with H3.3K27M-mutant gliomas after ex vivo expansion, indicating spontaneous H3.3K27M (26-35)-specific T-cell responses. Our published report independently described the same observations in our H3.3K27M-positive HLA-A*02:01 patient cohort. The spontaneous induction of the H3.3K27M (26-35)-specific CD8+ T-cell responses, observed in these two independent studies, strongly suggests that the epitope can be processed and presented by the immune system of HLA-A*02:01+H3.3K27M+DMG patients. Of course, non-tumor cells, such as DMG-infiltrating myeloid cells, may theoretically cross-present the DMG cell-derived H3.3K27M (26-35) epitope. However, the tumor microenvironment of DMG is known to have few inflammatory myeloid cells. Furthermore, although dural lymphatics may drain the antigens from the cerebral spinal fluid space to cervical lymph nodes, the draining route for protein antigens in the brain parenchyma has not been fully established. These considerations and observations still indicate that DMG cells can directly present the epitope.

The investigators mentioned that our H3.3K27M epitope vaccination study (PNOC007) did not improve the overall outcome in H3.3K27M-patients with DMG. However, in this study, the development of H3.3K27M-specific CD8+ T-cell response was associated with prolonged overall survival and progression-free survival of patients. We were keen to discern whether the observed H3.3K27M-reactive CD8+ T-cell responses merely reflected general immune competency, which is often compromised in patients with progressive tumors. Our multivariate analysis on bulk CD8+ T cells strongly suggested this was not the case. Another concern is the possibility that patients with intrinsically slow-growing tumors may have received more vaccines than those with fast-growing tumors, thereby mounting higher vaccine-reactive responses. Based on our analyses, this does not appear to be the case, as the median number of vaccines preceding immunological responses among responders was the same as the median number of total vaccines among nonresponders. Taken together, our data support that the H3.3K27M-specific CD8+ T-cell responses may have provided clinical benefits.

Finally, the investigators report that T cells expressing the TCR derived from the 1H5 clone reacted with both mutant and wild-type (WT) peptides. In sharp contrast, our T cells transduced with the retroviral vector encoding the 1H5 TCR and siRNA against endogenous TCR common chains reproducibly produced significantly higher response levels to H3.3K27M than the WT peptide. We demonstrated multiple lines of data to support this. First of all, as the investigators noted, there is a striking difference in the binding affinity of the mutant vs WT peptide to HLA-A*02:01. We included a data set from in vitro binding assays in addition to the predicted affinity based on algorithms. Using a competitive binding-inhibition assay, we determined that the half-maximal inhibitory concentration (IC50) values for the mutant and WT peptides are 151 nM and >3868 nM, respectively. Even if the 1H5 TCR recognizes the common amino acid sequence between the mutant and WT peptides, the marked difference in the HLA-binding capability between the two peptides should lead to
remarkably different levels of reactivity. Indeed, although we did report detectable levels of IFN-γ response on T2 cells loaded with extremely high concentrations (~10µg/mL) of WT peptide, the response was below background levels with lower concentrations (1–100ng/mL) WT peptide. In addition to the published data, we have now included a dataset from our intracellular cytokine assays (figure 1). Our report also includes a dataset from Alanine scanning assays. We cocultured J.RT3-T3.5 cells transduced with the 1H5 TCR and evaluated them for IL-2 production in response to T2 cells loaded with a series of synthetic peptides, including the H3.3 mutant and WT peptide (10µg/mL). Again, we showed a robust level of IL-2 production with the mutant peptide but merely background levels with the WT peptide.

In summary, while we agree with the investigators that the H3.3K27M (26-35) epitope may not be robustly presented by all HLA-A*02:01+DMG cells, our data and observations from both laboratory and clinical trials still support a role of this epitope in immunotherapy for HLA-A*02:01+ patients with DMG. Further investigations are warranted to develop strategies to enhance the role of the epitope as a target.

Author affiliations
1 Sanofi Genzyme, Cambridge, Massachusetts, USA
2 Department of Neurology, UCSF, San Francisco, California, USA
3 Department of Neurosurgery, UCSF, San Francisco, California, USA
4 Department of Pediatrics, UCSF, San Francisco, California, USA
5 Children’s University Hospital, Zurich, Switzerland
6 3T Biosciences Inc, Palo Alto, California, USA
7 Parker Institute for Cancer Immunotherapy, San Francisco, California, USA
8 Department of Microbiology and Immunology, UCSF, San Francisco, California, USA
9 Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA

Contributors All authors equally contributed to writing this letter. BH generated the data set presented in figure 1.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests No, there are no competing interests.
Patient consent for publication Not applicable.
Provenance and peer review Not commissioned; internally peer reviewed.
Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iD Hideho Okada http://orcid.org/0000-0003-0076-9920

REFERENCES